Showing 1 to 1 of 1 results
forbes.com
🌐 95% Global Worthiness
FDA Approves First Gene Therapy for RDEB, Showcasing Innovative Funding Model
The FDA approved ZEVASKYN, the first autologous cell-based gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a significant advancement driven by EB Research Partnership's innovative venture philanthropy model, offering hope to 500,000 people globally.
FDA Approves First Gene Therapy for RDEB, Showcasing Innovative Funding Model
The FDA approved ZEVASKYN, the first autologous cell-based gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a significant advancement driven by EB Research Partnership's innovative venture philanthropy model, offering hope to 500,000 people globally.
Progress
52% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results